Get started
Author

Bing Hou

Observed name: Bing HOU
Observed institutions: AstraZeneca (United Kingdom), Leeds General Infirmary, University of Leeds, St James's University Hospital, Northwest University, Antengene Corporation Limited (China), Menoufia University
ORCID: 0000-0002-8348-3831
Observed ORCID: 0000-0002-8348-3831
OpenAlex ID: A5048307356
Piezo1 integration of vascular architecture with physiological force
2014 · Jing Li, Bing Hou, et al. · Nature · 1,262
Orai1 and CRAC Channel Dependence of VEGF-Activated Ca 2+ Entry and Endothelial Tube Formation
2011 · Jing Li, Richard M. Cubbon, et al. · Circulation Research · 189
Pregnenolone Sulphate- and Cholesterol-Regulated TRPM3 Channels Coupled to Vascular Smooth Muscle Secretion and Contraction
2010 · Jacqueline Naylor, Jing Li, et al. · Circulation Research · 144
Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
2021 · Trinayan Kashyap, Jackelyn Murray, et al. · Antiviral Research · 63
Inhibition of endothelial cell Ca 2+ entry and transient receptor potential channels by S igma‐1 receptor ligands
2012 · Mohamed S Amer, Lynn McKeown, et al. · British Journal of Pharmacology · 50
PDF
An array of 60,000 antibodies for proteome-scale antibody generation and target discovery
2020 · Zhaohui Wang, Yang Li, et al. · Science Advances · 40
Orai3 Surface Accumulation and Calcium Entry Evoked by Vascular Endothelial Growth Factor
2015 · Jing Li, Alexander-Francisco Bruns, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 32
Radioactive 125I Seed Inhibits the Cell Growth, Migration, and Invasion of Nasopharyngeal Carcinoma by Triggering DNA Damage and Inactivating VEGF-A/ERK Signaling
2013 · Yunhong Tian, Qiang Xie, et al. · PLoS ONE · 28
PDF
Endothelial Piezo1: Life depends on it
2015 · Jing Li, Bing Hou, et al. · Channels · 23
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al. · Cancer Research · 21
Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate
2025 · Zhenguo Liang, Hui Xie, et al. · Journal of Autoimmunity · 4
893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation
2021 · Hui Yuwen, Tengteng Li, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
608 Synergistic effect of the combination of ATG-017, an ERK1/2 inhibitor, and immune checkpoint inhibitor in preclinical cancer models
2021 · Peng Chen, Yun Liu, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
896 A CD2-based costimulatory T cell engager platform integrating a novel CD3γε/δε-targeting antibody and steric-hindrance-based CD3 masking
2026 · Shuyu Huang, Mengshi Gao, et al. · Journal for ImmunoTherapy of Cancer
PDF
1068 ATG-107, a novel 2+1 CD3-based T cell engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML
2024 · Ao Sun, Rong Guo, et al. · Journal for ImmunoTherapy of Cancer
Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S6 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S3 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Supplementary Table S5 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation
2024 · Hui Yuwen, Huajing Wang, et al.
Abstract 2372: ATG-102, a novel LILRB4 x CD3 T cell engager, targeting two nonoverlapping epitopes of LILRB4, for the treatment of monocytic AML
2024 · Ao Sun, Mengshi Gao, et al. · Cancer Research
1112 Single-cell RNA sequencing reveals the positive feedback activation loop between T and dendritic cells induced by PD-L1x4–1BB bispecific antibody
2023 · Yunkai Zhang, Hui Yuwen, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 30
Citation count: 1,863
H-index: 10
I10-index: 10
Year
Topic
Type